Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624898 | 0.90 | HTR6 (0.60) | HTR6HTR2CHTR2ASLC6A4 | |
| SCHEMBL3616272 | 0.89 | HTR6 (0.51) | HTR6HTR2CHTR2ASLC6A4 | |
| SCHEMBL3618962 | 0.88 | HTR6 (0.60) | HTR6HTR2C | |
| SCHEMBL3622612 | 0.88 | HTR6 (0.53) | HTR6HTR2CHTR2ASLC6A4 | |
| SCHEMBL3623794 | 0.87 | HTR6 (0.49) | HTR6HTR2CHTR2ASLC6A4HSD11B1 | |
| SCHEMBL3623942 | 0.86 | HTR6 (0.53) | HTR6LMNA | |
| SCHEMBL3612952 | 0.84 | HTR6 (0.48) | HTR6HTR2CHTR2ASLC6A4 | |
| SCHEMBL3616792 | 0.83 | HTR6 (0.52) | HTR6HTR2CALDH1A1HTR2ASLC6A4 | |
| SCHEMBL3622073 | 0.83 | HTR6 (0.46) | HTR6HTR2CALDH1A1HTR2ASLC6A4 | |
| SCHEMBL3626596 | 0.83 | HTR6 (0.60) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184990-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | claimed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| WO-2009023844-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | WO | claimed |
| EP-2184990-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2009023844-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023844-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3A, HTR3B | HTR6 1/4885HTR2C 9/4885ALDH1A1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.